Panbela Therapeutics, Inc. (PBLA)
| Market Cap | 28.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.53M |
| Shares Out | 20.77M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,893 |
| Open | 1.35 |
| Previous Close | 1.31 |
| Day's Range | 1.31 - 1.37 |
| 52-Week Range | 0.59 - 2.54 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 8.16 (+495.6%) |
| Earnings Date | Aug 15, 2022 |
About PBLA
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic duct... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PBLA stock is "Buy." The 12-month stock price forecast is 8.16, which is an increase of 495.62% from the latest price.
News
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab...
Expects interim data by early 2024 Expects interim data by early 2024
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Pat...
MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medi...
Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results
MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medi...
Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Dieth...
MINNEAPOLIS, June 28, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . - (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet ...
Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.
MINNEAPOLIS, June 16, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today ann...
Panbela Provides Business Update and Reports Q1 2022 Financial Results
MINNEAPOLIS, May 12, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today prov...
PANBELA THERAPEUTICS INVESTOR ALERT - Kuznicki Law PLLC Investigates Panbela Therapeutics, Inc. - PBLA
CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to Panbela Therapeutics, Inc. (“the Company”) (NasdaqCM: PBLA). Under t...
Panbela to Host Virtual R&D Day
MINNEAPOLIS, April 27, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...
Panbela Schedules Conference Call on May 12, 2022, to Report 2022 First Quarter Financial Results
MINNEAPOLIS, April 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...
Panbela Announces Poster Presentation at American Association for Cancer Research:
The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine...
PANBELA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates ...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cancer Prevention ...
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results
MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today pr...
Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging In...
MINNEAPOLIS, March 23, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...
Panbela to Participate in the 34th Annual Roth Conference
MINNEAPOLIS, March 10, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...
Panbela Schedules Conference Call on March 24, 2022, to Report 2021 Fourth Quarter Financial Results
MINNEAPOLIS, March 08, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...
Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)
MINNEAPOLIS, March 07, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...
Panbela Therapeutics Acquires Cancer Prevention Pharmaceuticals For Stock & Milestone Payment
Panbela Therapeutics Inc (NASDAQ: PBLA) has agreed to acquire a privately-held Cancer Prevention Pharmaceuticals Inc (CPP) for a combination of stock and future milestone payments. The combined entity w...
PBLA Stock Investigation: Halper Sadeh LLP Is Investigating Whether the Merger of Panbela Therapeutics, Inc. Is Fair ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Panbela Therapeutics, Inc. (NASDAQ: PBLA) and Cancer Prevention Pharmaceuticals, Inc. is ...
Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.
MINNEAPOLIS, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today ann...
Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine Wit...
MINNEAPOLIS, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with...
Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitax...
MINNEAPOLIS, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with...
Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines;...
Company to host a virtual R&D day to discuss the new ovarian cancer program in the new year Company to host a virtual R&D day to discuss the new ovarian cancer program in the new year
Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointes...
MINNEAPOLIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with...
Panbela Provides Business Update and Reports Q3 2021 Financial Results
MINNEAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with...
Panbela Schedules Conference Call on November 10, 2021, to Report 2021 Third Quarter Financial Results
MINNEAPOLIS , Oct. 25, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients w...